Trinity Biotech announces financing transactions with Perceptive Advisors ($0.89, 0.00)
Follow-up: Trinity Biotech reports preliminary Q3 results, updates on pipeline developments, announces interim CFO transition ($0.89, 0.00)
Trinity Biotech announces order for 9M TrinScreen HIV tests ($0.89, 0.00)
Trinity Biotech expands global rollout of high-capacity column system for FDA-cleared HbA1c testing solution after securing regulatory clearances ($1.07, 0.00)
StreetAccount Activist Summary: Week of 1-Dec
AI n M acquires MiCo IVD for KRW5.0B ($3.4M), becomes major holder in Trinity Biotech - 13D/A ($1.00, 0.00)
Trinity Biotech secures WHO approval for Offshored and Outsourced Manufacturing of Its Uni-Gold Rapid HIV Test ($0.82, 0.00)
Trinity Biotech announces collaboration to advance epigenetic analysis for EpiCapture prostate cancer test
Trinity Biotech notes Perceptive Advisors' indication of potential debt-to-equity conversion ($1.00, 0.00)
Trinity Biotech announces in-country regulatory approval for offshored and outsourced manufacturing of its TrinScreen HIV rapid test ($1.37, 0.00)
Powered by FactSet Research Systems Inc.